Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2010

View Archived Issues

SCH-527123 shows potential in severe neutrophilic asthma

ROSE-010 acts via exendin receptor and is linked to treatment compliance in IBS

Snapshots: Phase III trials of meningococcal vaccine MenACWY-TT

sCD83 prevents renal allograft rejection in kidney transplantation models

ONO-5334 shows promise in postmenopausal osteoporosis

Tolcapone beneficial in patients with psychosis

EG-Mirotin restores blood flow in oxygen-induced retinopathy model

Shire updates progress of first quarter 2010

AstraZeneca describes novel inhibitors of Abeta production

Deciphera claims novel protein kinase inhibitors

New gamma-secretase modulators disclosed by Roche

Genentech identifies new Janus kinase inhibitors

NGR-hTNF cleared to enter phase III mesothelioma trial in U.S.

Pharming submits Rhucin MAA response to EMA

EpiCept launches Ceplene in Germany for acute myeloid leukemia

FDA accepts Clinical Data's vilazodone NDA for major depressive disorder

Can-Fite's phase II CF-101 trial in glaucoma approved in Israel

Abbott acquires Piramal's Healthcare Solutions business in India

FDA grants orphan drug status to RG-2833 in Friedreich's ataxia

Pro-Pharmaceuticals plans phase III trial of Davanat

Salix launches Xifaxax 550-mg tablets for hepatic encephalopathy

American Life Science receives ADDF grant to enable phase I AB-007 trials

Neuralstem progresses phase I trial of spinal cord stem cells in ALS

Enrollment initiated in phase III daclizumab trial in RRMS

Boehringer Ingelheim selects Nanobody lead to develop in AD

DMC recommends continued analysis of phase III deforolimus data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...